Evidence map›Paper›PMID 31813662›Full record

Observational studyClinical oncology (Royal College of Radiologists (Great Britain))2020

Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.

E Tzolos, P D Adamson, P S Hall, I R Macpherson, O Oikonomidou, M MacLean, S C Lewis, H McVicars, D E Newby, N L Mills and 2 more

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical oncology (Royal College of Radiologists (Great Britain)), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

E TzolosBHF Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK. Electronic address: e.tzolos@ed.ac.uk.
P D AdamsonBHF Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK; Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.
P S HallCancer Research UK, Edinburgh Centre, MRC Institute Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
I R MacphersonInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.
O OikonomidouCancer Research UK, Edinburgh Centre, MRC Institute Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
M MacLeanEdinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK.
S C LewisEdinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
H McVicarsCancer Research UK, Edinburgh Centre, MRC Institute Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
D E NewbyBHF Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK.
N L MillsBHF Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
N N LangDepartment of Cardiology, Queen Elizabeth University Hospital, Glasgow, UK.
P A HenriksenBHF Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK.
University of Edinburgh · GBEdinburgh Cancer Research · GBQueen Elizabeth University Hospital · GBUniversity of Glasgow · GB

Funding

British Heart Foundation FS/16/14/32023Department of Health EME/15/48/20
6 · The paper itself

Abstract

aimsTreatment advances have improved cancer-related outcomes and shifted interest towards minimising long-term iatrogenic complications, particularly chemotherapy-related cardiotoxicity. High-sensitivity cardiac troponin I (hs-cTnI) assays accurately quantify very low concentrations of plasma troponin and enable early detection of cardiomyocyte injury prior to the development of myocardial dysfunction. The profile of hs-cTnI in response to anthracycline-based treatment has not previously been described. MATERIALS AND

methodsThis was a multicentre prospective observational cohort study. Female patients with newly diagnosed invasive breast cancer scheduled to receive anthracycline-based (epirubicin) chemotherapy were recruited. Blood sampling was carried out before and 24 h after each cycle. Hs-cTnI concentrations were measured using the Abbott ARCHITECT

resultsWe recruited 78 women with a median (interquartile range) age of 52 (49-61) years. The median baseline troponin concentration was 1 (1-4) ng/l and the median cumulative epirubicin dose was 394 (300-405) mg/m

conclusionsCardiotoxicity arising from anthracycline therapy is detectable in the earliest stages of breast cancer treatment and is cumulative with each treatment cycle. This injury is most reliably determined from blood sampling carried out before rather than after each treatment cycle.

Indexed as

AnthracyclinesBiomarkersBreast NeoplasmsCardiotoxicityFemaleHumansMiddle AgedPrognosisProspective StudiesTroponin IAnthracyclinesBiomarkersTroponin IAnthracyclinebreast cancercardiotoxicityhigh-sensitivity cardiac troponinleft ventricular ejection fraction

Identifiers

PMID31813662
PMCPMC7139216
OpenAlexW2993929443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.